Combination Study With MVA BN and Dryvax
NCT00082446
Completed
The overall goals of this study are to expand the available data on the safety and immunogenicity of MVA-BN in vaccinia-naive adults and to determine the optimum dose of MVA-BN to induce immune responses and attenuate Dryvax take reactions. Participants will include 90 healthy volunteers, ages 18-32 years. Participants will be randomly assigned to 1 of 6 study groups (groups A-F). Participants will be involved in study related procedures for up to 2 years. During this time, volunteers will retur... Read More
Gender:
ALL
Ages:
Between 18 years and 32 years
Trial Updated:
12/18/2014
Locations: Saint Louis University, St. Louis, Missouri
Conditions: Smallpox
Register for Updates
Eldery High Dose TIV 2005
NCT00115531
Completed
The purpose of this study is to compare a new higher-dose influenza virus vaccine to the standard dose vaccine in elderly adults who can walk. Current influenza vaccines protect elderly against viral influenza but not as well as desired. It is expected that the higher doses vaccine can be given with little reaction, but this needs to be tested. Up to 410 people ages 65 years and older will be recruited from the community and from existing volunteer populations. Participants will receive either t... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
12/18/2014
Locations: University of Iowa - Vaccine Research & Education Unit, Iowa City, Iowa +4 locations
Conditions: Influenza
Register for Updates
ACAM 3000 MVA at Harvard Medical School
NCT00133575
Completed
The purpose of this study is to assess the safety of an experimental smallpox vaccine (MVA: Modified Vaccinia Ankara) and to compare the body's immune (system that fights disease) response to this vaccine. Participants will be assigned to 1 of 6 study groups. Each group will include 12 subjects, 10 will receive the modified smallpox vaccine and two will receive placebo, an inactive substance. The vaccine will be administered in 1 of 3 ways: under the skin; in the muscle; or between the muscle an... Read More
Gender:
ALL
Ages:
Between 18 years and 38 years
Trial Updated:
12/11/2014
Locations: Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts
Conditions: Smallpox
Register for Updates
Expanded Dryvax Dilution Study in Previously Vaccinated Adults
NCT00050505
Completed
The purpose of this study is to determine the safety and effect of diluting smallpox vaccine, making a larger number of doses in case smallpox is released into the environment. A total of up to 927 healthy adults between the ages of 32 and 70 years who were already vaccinated against smallpox (but not since 1989) will volunteer for this study for up to 34 weeks and receive different strengths of vaccine. Some subjects may participate for longer if they choose to be revaccinated because the first... Read More
Gender:
ALL
Ages:
Between 32 years and 70 years
Trial Updated:
12/04/2014
Locations: Kaiser Permanente Vaccine Study Center, Oakland, California +6 locations
Conditions: Smallpox
Register for Updates
FLU-VACS Comparative Study in Adults
NCT00133523
Completed
The purpose of this study is to compare 2 licensed flu vaccines to each other and to placebo (inactive substance). The study will be conducted among healthy adult participants aged 18-49 years and is expected to last 3 years. During year 1, participants will be assigned to receive 1 of the 2 licensed flu vaccines or placebo, given as either nasal spray (live-attenuated vaccine or placebo) or injection (inactivated vaccine or placebo). Participants will receive the same assigned vaccine or placeb... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
12/04/2014
Locations: Ann Arbor West, Ann Arbor, Michigan +5 locations
Conditions: Influenza
Register for Updates
Comparison of Delivery Routes of Flu Vaccine in Adults
NCT00170547
Completed
This protocol is to compare the immune response of different influenza vaccines given by two different routes of administration in healthy adults ages 18 to 64 years.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
12/04/2014
Locations: Stanford University School of Medicine, Stanford, California +9 locations
Conditions: Influenza
Register for Updates
Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma
NCT00307177
Completed
The purpose of this research is to compare reactions and antibody responses following receipt of different doses of the experimental influenza vaccine or standard influenza vaccine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2014
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Influenza
Register for Updates
2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
NCT01173211
Completed
The purpose of this study is to see how much antibody (proteins produced by the immune system that help fight infections) the body makes after getting a flu vaccine. Researchers will also look at how the body reacts to the flu vaccine and how it affects the babies of pregnant women. The study will enroll approximately 240 women ages 18-39 years, including 180 pregnant women in their second or third trimester of pregnancy (at least 14 weeks pregnant) and 60 non-pregnant women. Participants will b... Read More
Gender:
FEMALE
Ages:
Between 18 years and 39 years
Trial Updated:
12/04/2014
Locations: Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri +4 locations
Conditions: Influenza
Register for Updates
TIV and High Dose TIV in Subjects With Rheumatoid Arthritis
NCT01436370
Completed
A randomized, double-blinded, Phase II study in adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy aged 18 to 64 years of age and healthy gender-and age-matched control subjects . This study will investigate the immunogenicity, safety, and reactogenicity of two different doses of inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone \[15 mcg x 3 strains\] and Sanofi Pasteur Fluzone High Dose \[60 mcg x 3 strains\]) administered intramuscularly in individuals w... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
12/04/2014
Locations: University of Iowa - Vaccine Research & Education Unit, Iowa City, Iowa
Conditions: Influenza
Register for Updates
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
NCT01254175
Completed
Human parainfluenza virus type 3 (HPIV3) is a major cause of pneumonia and other respiratory diseases in infants and children. This study will evaluate the safety and immune response of an HPIV3 vaccine in infants and young children.
Gender:
ALL
Ages:
Between 6 months and 36 months
Trial Updated:
12/02/2014
Locations: Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California +7 locations
Conditions: Parainfluenza Virus 3, Human
Register for Updates
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults
NCT00715910
Completed
In this study, the concentration of antibody to the vaccine one year, three and five years after vaccination in subjects who were vaccinated with GSK Biologicals' meningococcal vaccine GSK134612 and Menactra® in a previous study (whose objectives \& outcome measures are presented in a separate protocol posting with NCT number =00454909) will be evaluated. The safety and immune response to a booster dose of vaccine GSK134612 administered at 5 years post-primary vaccination and a primary vaccinati... Read More
Gender:
ALL
Ages:
Between 15 years and 30 years
Trial Updated:
11/20/2014
Locations: GSK Investigational Site, Daly City, California +9 locations
Conditions: Infections, Meningococcal
Register for Updates
Alternate Dosing Schedules Study for HPV Vaccine
NCT00862810
Completed
To determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicits an equivalent immune response (geometric mean titers to HPV 6,11,16, and 18 as measured one month after receipt of a 3rd dose of HPV vaccine) when compared to vaccine delivered according to the recommended dosing schedule. This is a prospective observational study of healthy 9-18 year old female patients receiving either a second or third dose of... Read More
Gender:
FEMALE
Ages:
Between 9 years and 18 years
Trial Updated:
11/19/2014
Locations: Chapel Hill Pediatrics, Chapel Hill, North Carolina +2 locations
Conditions: Cervical Cancer, Genital Warts
Register for Updates